A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/215 (2006.01) C12Q 1/70 (2006.01)
Patent
CA 2595780
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
L'invention concerne un anticorps isolé capable de se lier au domaine de liaison au récepteur de la protéine spicule du coronavirus associé au syndrome respiratoire aigu sévère (SARS-CoV) afin d'inhiber, de manière compétitive, la liaison du SARS-CoV avec des cellules hôtes. On peut utiliser ces mAbs ou substances: 1) comme agents d'immunisation passive pour prévenir une infection par le SARS-CoV; 2) comme réactifs biologiques pour diagnostiquer une infection par le SARS-CoV; 3) comme thérapies immunitaires pour traiter précocement une infection par le SARS-CoV; et 4) comme sondes pour étudier l'immunogénicité, l'antigénicité, la structure et la fonction de la protéine SARS- CoV S.
He Yuxian
Jiang Shibo
New York Blood Center Inc.
Smart & Biggar
LandOfFree
Neutralizing monoclonal antibodies against severe acute... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing monoclonal antibodies against severe acute..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing monoclonal antibodies against severe acute... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1411665